NEJM· C. Michael Gibson P. Gabriel Steg M. Cecilia Bahit Rasha Al-Lamee Shamir R. Mehta Roxana Mehran Jeffrey I. Weitz Shinya Goto Jose Carlos Nicolau Renato D. Lopes Junbo Ge Nebojsa Tasic Dominick J. Angiolillo Suzanne J. Baron Ajay J. Kirtane Denis Xavier Satoshi Yasuda Basil S. Lewis Duk-Woo Park Jan H. Cornel Thomas W. Johnson Jaroslaw Trebacz Daniel Duerschmied Christoph Bode Bela Merkely Maria Dorobantu Dragos Vinereanu Zuzana Motovska Hector Bueno Jose Luis Lopez-Sendon Gregory Ducrocq Giuseppe Ambrosio Lesley Burgess Allan Bohm Chern-En Chiang Joao Morais Alan Fong Umit Guray Jose Luis Leiva-Pons Pascal Vranckx Harvey D. White Sasko Kedev Marco Valgimigli Duško Cerovec Dimitris Tousoulis Gemma Figtree Thuong Dung Ho Rody G. Sy Morten Bøttcher Kurt Huber Rimvydas Slapikas Andrejs Erglis Jack Wei Chieh Tan Christian Pincetti Karen S. Pieper Kenneth W. Mahaffey Carolyn S.P. Lam S. Claiborne Johnston Graeme J. Hankey Jennifer S. Li Luke Zheng Ronald Aronson Danshi Li Ravi Notani Philippe Vieira Pires Thomas J. Povsic Alistair C. Lindsay Alexei Plotnikov Hsiaowei Deng Elliot S. Barnathan and Robert A. Harringtonthe LIBREXIA ACS Committees and Investigators*·· 2026-08-29AI 评分42
Milvexian 联合抗血小板治疗用于急性冠脉综合征事件后
Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event
AI 导读
在急性冠脉综合征事件后患者中，口服因子 XIa 抑制剂 Milvexian 联合抗血小板治疗相比安慰剂未显著降低缺血性事件风险，但出血风险呈剂量依赖性增加。该 Phase 2 试验纳入 1,562 例患者，主要疗效终点为心血管死亡、心肌梗死、卒中或支架内血栓形成的复合终点，Milvexian 各剂量组均未达到预设优效性。安全性方面，高剂量组大出血或临床相关非大出血事件发生率高于安慰剂组。
来源：NEJM · nejm.org